[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT05598879":3,"trial-entities:NCT05598879":104,"trial-summary:NCT05598879":116},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":6,"overall_status":7,"completion_date":8,"status_verified_date":9,"last_update_date":10,"start_date":11,"sponsor_name":12,"lead_sponsor_class":13,"has_dmc":14,"brief_summary":15,"detailed_description":16,"conditions":17,"keywords":23,"study_type":32,"primary_purpose":33,"phases":34,"enrollment_info":35,"interventions":38,"primary_outcomes":46,"secondary_outcomes":56,"sex":57,"minimum_age":58,"maximum_age":33,"healthy_volunteers":59,"eligibility_criteria":60,"std_ages":73,"locations":76,"central_contacts":92,"overall_officials":99,"references":102,"see_also_links":103},"NCT05598879","IRB 22-211","Global Cardio Oncology Registry","RECRUITING","2029-07-01","2026-05","2026-05-12","2022-07-01","The Cleveland Clinic","OTHER",true,"G-COR is the first Global Prospective Cardio-Oncology Registry. It is a multinational, multicenter prospective observational cohort registry, with the goal of collecting clinical, laboratory, imaging, demographic, and socioeconomic data to identify risk factors associated with increased incidence of cancer therapy related cardiovascular toxicity (CTR-CVT) in different settings and to derive and validate risk scores for cardio oncology patients treated in different geographic locations throughout the world.","G-COR is the first Global Prospective Cardio-Oncology Registry. It is a multinational, multicenter prospective observational cohort registry, with the goal of collecting clinical, laboratory, imaging, demographic, and socioeconomic data to identify risk factors associated with increased incidence of cancer therapy related cardiovascular toxicity (CTR-CVT) in different settings and to derive and validate risk scores for cardio oncology patients treated in different geographic locations throughout the world.\n\nG-COR will involve the collaboration from 124 hospitals from 24 countries that completed survey with sites demographics. It will evaluate cardiovascular disease in three distinct populations of cancer patients (hematological malignancies: lymphomas, leukemias, multiple myeloma; breast cancer patients; and patients treated with check point inhibitors immunotherapy).\n\nG-COR will evaluate the cardiovascular impact of different cancer treatments in the above-described patients, and similarities and differences in diagnostic and treatment modalities as well as outcomes and the impact of socioeconomic factors and risk factors for toxicities in a large worldwide population.\n\nG-COR will study the impact of cancer in CV disease in cancer patients treated at academic centers as well as in patients treated at community hospitals, through a systematic prospective data collection in a global digital platform.\n\nG-COR is an IRB approved prospective registry, conducted with the logistical support of C5 Clinical Research Division and the Cardiovascular Outcomes Registries and Research (CORR) group at the Cleveland Clinic and have developed eCRFs with an extensive Red Cap Cloud platform.\n\nG-COR Executive, Scientific and topic committees are led by North American, European, Latin American, Australian and Asian representatives from both academic and community centers.\n\nG-COR Pilot US, was completed (phase 1) with breast cancer patients from 18 US Centers and enrolled 700 patients.\n\nG-COR Global Phase 2, has now started enrolling patients from the three pillars (-breast cancer, -hematological malignancies, and -patients treated with immune check point inhibitors (ICI). Enrollment of phase 2 started in early 2026 and will continue with enrollment and follow up until July 2029.\n\nG-COR Global International will start in 2026 with centers from Europe, Latin America, Australia, Asia and Africa.",[18,19,20,21,22],"Breast Cancer","Hematologic Malignancy","Immune Checkpoint Inhibitor-Related Myocarditis","Cardiotoxicity","Cardiovascular Diseases",[24,25,26,27,28,29,30,31],"cardiotoxicity","Cancer related cardiovascular diseases","prospective registry","international collaboration","social determinants of health","health care disparities","real world data","cardiology-oncology team work","OBSERVATIONAL",null,[],{"count":36,"type":37},5000,"ESTIMATED",[39],{"type":13,"name":40,"description":41,"armGroupLabels":42},"anonymized data collection during programmed surveillance clinical follow up","anonymized data entry of demographic, clinical, imaging, laboratory, cancer treatment, and cardiovascular events into a RedCap Cloud platform",[43,44,45],"Breast cancer","Hematological malignancies","Immune check point inhibitors",[47,50,53],{"measure":21,"description":48,"timeFrame":49},"Any new cardiac event occurring during or after cancer treatment","18 months of prospective follow up",{"measure":51,"description":52,"timeFrame":49},"New cardiovascular events","Heart failure, myocardial infarction, cardiac arrhythmias, syncope, coronary revascularization, heart transplant, cerebrovascular accident, peripheral arterial disease, hypertension, pulmonary hypertension. All events will be adjudicated according to standard clinical definitions.",{"measure":54,"description":55,"timeFrame":49},"Cardiovascular death.","Death during or after cancer treatment, adjudicated to cardiovascular causes by treating physicians.",[],"ALL","18 Years",false,{"inclusion":61,"exclusion":68,"raw_text":72},[62,63,64,65,66,67],"New cardio-oncology consultation for breast cancer patients, or","New cardio-oncology consultation for Hodgkin's or non-Hodgkin's lymphoma patients, or","New cardio-oncology consultation for acute or chronic leukemia patients, or","New cardio-oncology consultation for multiple myeloma or AL amyloidosis, or","New cardio-oncology consultations for immune check-point inhibitors cardiac evaluation.","All patients have to be 18 years old or older",[69,70,71],"Cardio-oncology patients who have previously had cardio-oncology evaluation and follow up by the investigators.","Minors less than 18 years old.","Inability or unwillingness to consent to participate","Inclusion Criteria:\n\n* New cardio-oncology consultation for breast cancer patients, or\n* New cardio-oncology consultation for Hodgkin's or non-Hodgkin's lymphoma patients, or\n* New cardio-oncology consultation for acute or chronic leukemia patients, or\n* New cardio-oncology consultation for multiple myeloma or AL amyloidosis, or\n* New cardio-oncology consultations for immune check-point inhibitors cardiac evaluation.\n* All patients have to be 18 years old or older\n\nExclusion Criteria:\n\n* Cardio-oncology patients who have previously had cardio-oncology evaluation and follow up by the investigators.\n* Minors less than 18 years old.\n* Inability or unwillingness to consent to participate",[74,75],"ADULT","OLDER_ADULT",[77],{"facility":78,"status":7,"city":79,"state":80,"zip":81,"country":82,"contacts":83,"geoPoint":89},"Cleveland Clinic Florida","Weston","Florida","33331","United States",[84],{"name":85,"role":86,"phone":87,"email":88},"Diego Sadler, MD FACC","CONTACT","561-389-8833","sadlerd@ccf.org",{"lat":90,"lon":91},26.10037,-80.39977,[93,95],{"name":85,"role":86,"phone":94,"email":88},"5613898833",{"name":96,"role":86,"phone":97,"email":98},"Rohit Moudgil, MD PhD","216-445-1932","moudgir@ccf.org",[100],{"name":85,"affiliation":12,"role":101},"PRINCIPAL_INVESTIGATOR",[],[],{"nct_id":4,"conditions":105,"biomarkers":115},[106,107,108,109,110,111,112,113,114],"Breast Carcinoma","Hematologic Neoplasm","Hodgkin's Granuloma","Immune Checkpoint Inhibitor-related Myocarditis","Leukemia","Multiple Myeloma","Non-Hodgkin Lymphoma","Primary Amyloidosis","Solid Neoplasm",[],{"nct_id":4,"found":14,"summary":117,"prompt_version":127},{"design":118,"status":119,"heading":120,"summary":121,"follow_up":122,"word_count":123,"commitments":124,"compensation":125,"drugs_mentioned":126},"This is an observational study, meaning researchers will collect information without giving any specific treatments. It plans to include 5000 participants.","completed","Global Cardio Oncology Registry (G-COR)","This study, called G-COR, is collecting information from 5000 people to better understand how cancer treatments affect the heart. It focuses on patients with breast cancer, certain blood cancers (like lymphoma and leukemia), and those receiving immunotherapy (immune checkpoint inhibitors). The study will gather anonymous health information, including demographics, medical history, imaging results, lab tests, cancer treatments, and any heart-related events. The main goals are to identify risk factors for heart problems caused by cancer treatments and to develop tools to predict these risks. You might be able to join if you are 18 or older and are having a new consultation with a cardio-oncology specialist for one of the specified cancer types.","Researchers will track cardiotoxicity, new cardiovascular events, and cardiovascular death for 18 months after you join the study.",113,"You would allow researchers to collect your anonymous health data during your regular clinical follow-up appointments.","Not stated in the trial record.",[],"v2"]